Cost Effectiveness of Ulcerative Colitis Surveillance in the Setting of 5-Aminosalicylates

Rubenstein, Joel H.; Waljee, Akbar K.; Jeter, Joanne M.; Velayos, Fernando S.; Ladabaum, Uri; Higgins, Peter D. R.
September 2009
American Journal of Gastroenterology;Sep2009, Vol. 104 Issue 9, p2222
Academic Journal
OBJECTIVES:Colorectal cancer (CRC) is a feared complication of chronic ulcerative colitis (UC). Annual endoscopic surveillance is recommended for the detection of early neoplasia. 5-Aminosalicylates (5-ASAs) may prevent some UC-associated CRC. Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs.METHODS:We performed systematic reviews of the literature, and created a Markov computer model simulating a cohort of 35-year-old men with chronic UC, followed until the age of 90 years. Twenty-two strategies were modeled: natural history (no 5-ASA or surveillance), surveillance without 5-ASA at intervals of 1–10 years, 5-ASA plus surveillance every 1–10 years, and 5-ASA alone. The primary outcome was the ideal interval of surveillance in the setting of 5-ASA maintenance, assuming a third-party payer was willing to pay $100,000 for each quality-adjusted life-year (QALY) gained.RESULTS:In the natural history strategy, the CRC incidence was 30%. Without 5-ASA, annual surveillance was the ideal strategy, preventing 89% of CRC and costing $69,100 per QALY gained compared with surveillance every 2 years. 5-ASA alone prevented 49% of CRC. In the setting of 5-ASA, surveillance every 3 years was ideal, preventing 87% of CRC. 5-ASA with surveillance every 2 years cost an additional $147,500 per QALY gained, and 5-ASA with annual surveillance cost nearly $1 million additional per QALY gained compared with every 2 years. In Monte Carlo simulations, surveillance every 2 years or less often was ideal in 95% of simulations.CONCLUSIONS:If 5-ASA is efficacious chemoprevention for UC-associated CRC, endoscopic surveillance might be safely performed every 2 years or less often. Such practice could decrease burdens to patients and on endoscopic resources with a minimal decrease in quality-adjusted length of life, because 5-ASA with annual surveillance may cost nearly $1 million per additional QALY gained.


Related Articles

  • The Endoscopy Corner. Morris, Steven J.; Greenwald, Richard A.; Tedesco, Francis J.; Waye, Jerome D. // American Journal of Gastroenterology;Aug1978, Vol. 70 Issue 2, p194 

    Presents a study on an acute ulcerative colitis mimicking an obstructing carcinoma of the colon. Occurrence of inflammatory pseudopolyposis in cases of ulcerative colitis; Medical diagnosis of the patient; Significance of the proctoscopic colonoscopic and anti-inflammatory therapy used in the...

  • Safety of Surveillance Colonoscopy in Long-standing Ulcerative Colitis. Koobatian, Gregor J.; Choi, Paul M. // American Journal of Gastroenterology;Sep1994, Vol. 89 Issue 9, p1472 

    Objective: Because of the increased risk of colorectal cancer in patients with long-standing ulcerative colitis, colonoscopic surveillance for the detection of dysplasia is currently recommended as a method of identifying high-risk patients. However, the hazard of colonoscopy with multiple...

  • Evaluation of Mucosal Healing of Ulcerative Colitis by a Quantitative Fecal Immunochemical Test. Nakarai, Asuka; Kato, Jun; Hiraoka, Sakiko; Kuriyama, Motoaki; Akita, Mitsuhiro; Hirakawa, Tomoko; Okada, Hiroyuki; Yamamoto, Kazuhide // American Journal of Gastroenterology;Jan2013, Vol. 108 Issue 1, p83 

    OBJECTIVES:Accumulating evidence has underlined the importance of mucosal healing as a treatment goal for ulcerative colitis (UC). Quantitative fecal immunochemical tests (FITs), which can rapidly quantify fecal blood with automated equipment, have been used recently to screen for colorectal...

  • Mesalazine effective in ulcerative colitis, but at cost.  // PharmacoEconomics & Outcomes News;7/29/2006, Issue 508, p8 

    The article focuses on a study on the cost effectiveness of the use of maintenance mesalazine, an aminosalicylate, in the treatment of ulcerative colitis. According to the study, the cost per quality-adjusted life-year (QALY) gained may be substantial unless quality of life improvements exceed...

  • Ulcerative Colitis: A Clearer Picture. Dworken, Harvey J. // Annals of Internal Medicine;Nov83, Vol. 99 Issue 5, p717 

    Editorial. Presents a study of patients with chronic ulcerative colitis in Scotland. Mortality rate of the disease; Diagnosis of patients; Risk of colonic cancer among patients with the disease.

  • Ulcerative colitis in the elderly: clinical patterns and outcome in 51 Greek patients. Triantafillidis, John K.; Emmanouilidis, Anastasios; Pomonis, Efstathios; Cheracakis, Petros; Hereti, Irini; Merikas, Emmanuel; Nicolakis, Dimitrios; Argyros, Nikolaos // Journal of Gastroenterology;2001, Vol. 36 Issue 5, p312 

    Purpose: In this study, the clinical characteristics and course of all patients with ulcerative colitis in whom diagnosis of the disease was made at or after the age of 60 (older group), were analyzed and compared with those of patients with ulcerative colitis in whom diagnosis of the disease...

  • Diagnosis and Treatment of Patients with Pouchitis. Shen, B. // Drugs;2003, Vol. 63 Issue 5, p453 

    Pouchitis is the most common long-term complication of ileal pouch-anal anastomosis in patients with underlying ulcerative colitis. Clinical symptoms of pouchitis are not specific, and they can be caused by other conditions such as rectal cuff inflammation and irritable pouch syndrome....

  • The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the ß-catenin signaling pathway. Munding, Johanna; Ziebarth, Wibke; Pox, Christian P.; Ladigan, Svetlana; Reiser, Markus; Hüppe, Dietrich; Brand, Linda; Schmiegel, Wolff; Tannapfel, Andrea; Reinacher-Schick, Anke C. // Carcinogenesis;Mar2012, Vol. 33 Issue 3, p637 

    Surveillance colonoscopy is an important strategy for prevention of colorectal cancer. 5-aminosalicylate (ASA) (mesalazine) is discussed as a chemopreventive agent as it reduces the cancer risk in ulcerative colitis patients. The current study analyses the effect of 5-ASA on Wnt/β-catenin...

  • Will a 5-ASA a Day Keep the Cancer (and Dysplasia) Away? Rubin, David T.; Lashner, Bret A. // American Journal of Gastroenterology;Jun2005, Vol. 100 Issue 6, p1354 

    Prevention strategies for colorectal cancer in chronic ulcerative colitis (UC) are currently based on the identification of neoplasia by surveillance colonoscopy, but there is a great interest in the possibility of primary chemoprevention. 5-aminosalicylic acid (5-ASA) therapy is an attractive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics